[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,026,093
  • Shares Outstanding, K 444,196
  • Annual Sales, $ 49,800 K
  • Annual Income, $ -50,340 K
  • EBIT $ -24 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.05
  • Price/Sales 20.87
  • Price/Cash Flow N/A
  • Price/Book 4.89

Options Overview Details

View History
  • Implied Volatility 121.58% (+5.39%)
  • Historical Volatility 62.25%
  • IV Percentile 35%
  • IV Rank 11.23%
  • IV High 421.18% on 02/09/26
  • IV Low 83.67% on 07/20/26
  • Expected Move (DTE 20) 0.13 (5.52%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 130
  • Volume Avg (30-Day) 367
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 31,105
  • Open Int (30-Day) 34,168
  • Expected Range 2.18 to 2.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 2
  • High Estimate $-0.05
  • Low Estimate $-0.06
  • Prior Year $0.01
  • Growth Rate Est. (year over year) -600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.04 +13.24%
on 07/15/26
2.44 -5.33%
on 07/02/26
-0.09 (-3.75%)
since 06/30/26
3-Month
1.52 +51.97%
on 05/07/26
2.68 -13.81%
on 06/30/26
+0.70 (+43.48%)
since 04/30/26
52-Week
1.01 +128.53%
on 07/31/25
2.68 -13.81%
on 06/30/26
+1.29 (+126.47%)
since 07/30/25

Most Recent Stories

More News
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August...

LXRX : 2.31 (-1.28%)
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc....

LXRX : 2.31 (-1.28%)
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1 diabetes...

LXRX : 2.31 (-1.28%)
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies...

LXRX : 2.31 (-1.28%)
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C....

LXRX : 2.31 (-1.28%)
Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter...

LXRX : 2.31 (-1.28%)
Lexicon: Q1 Earnings Snapshot

Lexicon: Q1 Earnings Snapshot

LXRX : 2.31 (-1.28%)
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

SONATA-HCM anticipated to be fully enrolled mid-2026  Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical...

LXRX : 2.31 (-1.28%)
Lexicon Pharmaceuticals: Whether the Pipeline Narrative Can Justify the Valuation

Barchart Research What to Expect from LXRX Earnings LXRX Generated May 6, 2026 Current Price $1.6000 EPS Estimate $$-0.04 Consensus Rating Moderate Buy Average Move 8.55% Lexicon Pharmaceuticals: Whether...

LXRX : 2.31 (-1.28%)
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC)...

LXRX : 2.31 (-1.28%)
HTGC : 16.42 (+3.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 2.46
2nd Resistance Point 2.41
1st Resistance Point 2.36
Last Price 2.31
1st Support Level 2.25
2nd Support Level 2.20
3rd Support Level 2.15

See More

52-Week High 2.68
Last Price 2.31
Fibonacci 61.8% 2.04
Fibonacci 50% 1.85
Fibonacci 38.2% 1.65
52-Week Low 1.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.